The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Neulasta (Pegfilgrastim) and Biosimilar Market Research Report 2024

Global Neulasta (Pegfilgrastim) and Biosimilar Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1739063

No of Pages : 91

Ask Your Query

Synopsis
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.

Global Neulasta (Pegfilgrastim) and Biosimilar market is projected to reach US$ 3773.3 million in 2029, increasing from US$ 2431 million in 2022, with the CAGR of 6.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Neulasta (Pegfilgrastim) and Biosimilar market research.

Key manufacturers engaged in the Neulasta (Pegfilgrastim) and Biosimilar industry include Amgen, Viatris, Coherus, Novartis, Pfizer, Amneal Pharmaceutical and Fresenius Kabi, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Neulasta (Pegfilgrastim) and Biosimilar were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Neulasta (Pegfilgrastim) and Biosimilar market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Neulasta (Pegfilgrastim) and Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Amgen
  • Viatris
  • Coherus
  • Novartis
  • Pfizer
  • Amneal Pharmaceutical
  • Fresenius Kabi

Segment by Type

  • Brand
  • Biosimilar

Segment by Application

  • Hospital
  • Pharmacy
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Neulasta (Pegfilgrastim) and Biosimilar report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Neulasta (Pegfilgrastim) and Biosimilar Market Overview
1.1 Product Overview and Scope of Neulasta (Pegfilgrastim) and Biosimilar
1.2 Neulasta (Pegfilgrastim) and Biosimilar Segment by Type
1.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Type (2023-2029)
1.2.2 Brand
1.2.3 Biosimilar
1.3 Neulasta (Pegfilgrastim) and Biosimilar Segment by Application
1.3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue 2018-2029
1.4.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales 2018-2029
1.4.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Neulasta (Pegfilgrastim) and Biosimilar Market Competition by Manufacturers
2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Manufacturers (2018-2023)
2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturers (2018-2023)
2.4 Global Neulasta (Pegfilgrastim) and Biosimilar Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Product Type & Application
2.7 Neulasta (Pegfilgrastim) and Biosimilar Market Competitive Situation and Trends
2.7.1 Neulasta (Pegfilgrastim) and Biosimilar Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Neulasta (Pegfilgrastim) and Biosimilar Players Market Share by Revenue
2.7.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neulasta (Pegfilgrastim) and Biosimilar Retrospective Market Scenario by Region
3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region: 2018-2029
3.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region: 2018-2023
3.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region: 2024-2029
3.3 Global Neulasta (Pegfilgrastim) and Biosimilar Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2018-2029
3.3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2018-2023
3.3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2024-2029
3.4 North America Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.4.1 North America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2029)
3.4.3 North America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.5.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2029)
3.5.3 Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.6.1 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2029)
3.6.3 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2029)
3.7.3 Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2029)
3.8.3 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2018-2029)
4.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2018-2023)
4.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2024-2029)
4.1.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2018-2029)
4.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2018-2029)
4.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2018-2023)
4.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2024-2029)
4.2.3 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2018-2029)
4.3 Global Neulasta (Pegfilgrastim) and Biosimilar Price by Type (2018-2029)
5 Segment by Application
5.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2018-2029)
5.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2018-2023)
5.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2024-2029)
5.1.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2018-2029)
5.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2018-2029)
5.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2018-2023)
5.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2024-2029)
5.2.3 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application (2018-2029)
5.3 Global Neulasta (Pegfilgrastim) and Biosimilar Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Viatris
6.2.1 Viatris Corporation Information
6.2.2 Viatris Description and Business Overview
6.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.2.5 Viatris Recent Developments/Updates
6.3 Coherus
6.3.1 Coherus Corporation Information
6.3.2 Coherus Description and Business Overview
6.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.3.5 Coherus Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Amneal Pharmaceutical
6.6.1 Amneal Pharmaceutical Corporation Information
6.6.2 Amneal Pharmaceutical Description and Business Overview
6.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.6.5 Amneal Pharmaceutical Recent Developments/Updates
6.7 Fresenius Kabi
6.6.1 Fresenius Kabi Corporation Information
6.6.2 Fresenius Kabi Description and Business Overview
6.6.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.7.5 Fresenius Kabi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Chain Analysis
7.2 Neulasta (Pegfilgrastim) and Biosimilar Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neulasta (Pegfilgrastim) and Biosimilar Production Mode & Process
7.4 Neulasta (Pegfilgrastim) and Biosimilar Sales and Marketing
7.4.1 Neulasta (Pegfilgrastim) and Biosimilar Sales Channels
7.4.2 Neulasta (Pegfilgrastim) and Biosimilar Distributors
7.5 Neulasta (Pegfilgrastim) and Biosimilar Customers
8 Neulasta (Pegfilgrastim) and Biosimilar Market Dynamics
8.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Trends
8.2 Neulasta (Pegfilgrastim) and Biosimilar Market Drivers
8.3 Neulasta (Pegfilgrastim) and Biosimilar Market Challenges
8.4 Neulasta (Pegfilgrastim) and Biosimilar Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock